Highlights Biophytis S.A.

Equities

ALBPS

FR001400OLP5

Real-time Euronext Paris Other stock markets 08:10:25 2024-07-12 am EDT			5-day change	1st Jan Change
0.575 ^EUR	0.00%		-0.86%	-71.81%

10:02am	BIOPHYTIS : Invest Securities confirms its recommendation	CF
Jul. 11	Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BIOPHYTIS : Invest Securities confirms its recommendation	04:02am	CF
Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	Jul. 11	MT
Biophytis: approval for a clinical trial in the USA	Jul. 11	CF
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity	Jul. 11	CI
Biophytis SA Presents Roll-Out and Results of Its Phase 2-3 Cova Study Results in Severe Forms of Covid-19 At the World Congress on Infectious Diseases	Jul. 01	CI
Biophytis: cash position strengthened, share price soars	Jun. 20	CF
Biophytis Extends Bond Financing Deal with Investment Fund Atlas	Jun. 20	MT
Biophytis S.A. Grants Blanver Exclusive Rights to Bio101 in Latin America in Deal Valued At Up to ?108 Million	Jun. 20	CI
Biophytis S.A. Announces the Successful Industrial Transfer of Bio101 (20-Hydroxyecdysone) Production by Its Service Provider Seqens	Jun. 14	CI
Biophytis: application filed in obesity in the USA	Jun. 10	CF
Biophytis SA Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity	Jun. 10	CI
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity	May. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Secure my Investments

fermer